CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Safety and Efficacy of CD22/CD19 CAR T-cells and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Sheng-Li Xue, M.D.
- Phone Number: +86 512 67781139
- Email: slxue@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital of Soochow University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- subjects with a primary diagnosis of B-ALL who have any of the following: (a) no suitable allogeneic HSCT donor. (b) refusal of allogeneic HSCT.
- positive expression of CD19 and CD22 in peripheral blood or bone marrow primary cells detected by flow cytometry.
- cardiac ultrasound left ventricular ejection fraction ≥ 50%; Creatinine ≤ 1.6 mg/dl; alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the normal range and total bilirubin ≤ 2.0 mg/dl; Pulmonary function ≤ grade 1 dyspnea (CTCAE v5.0) with oxygen saturation > 91% without oxygenation.
- subjects aged 15-65 years (including 15 and 65 years), regardless of gender.
- T-cell amplification test pass.
- expected survival > 3 months.
Exclusion Criteria:
- patients with recurrence of only isolated extramedullary lesions.
- combination of other malignant tumors.
- previously treated with anti-CD19 or/and CD22 or/and CD3 therapies.
- immunosuppressants use within 2 weeks prior to signing informed consent or plan to immunosuppressants after signing informed consent.
- uncontrolled active infections.
- HIV infection.
- active hepatitis B or hepatitis C infection.
- history of severe tachyphylaxis to aminoglycoside antibiotics.
- history or presence of clinically relevant Central Nervous System (CNS) pathology, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CD22/CD19 CAR T and auto-HSCT sandwich strategy as consolidation therapy for B-ALL
|
The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5*10^6/kg respectively) after standard induction and consolidation chemotherapy.
Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion.
Modified BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection.
CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT.
Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: 2 years
|
It is measured from the date of the first CAR-T (CAR-T 1) to the date of death from any cause; subjects not known to have died at last follow-up are censored on the date they were last known to be alive
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Leukemia-free survival (LFS)
Time Frame: 2 years
|
It is measured from the date of achievement of a remission after CAR-T 1 until the date of relapse from CR, or CRi, or death from any cause; subjects not known to have any of these events are censored on the date they were last examined.
|
2 years
|
|
Measurable residual disease (MRD) negative rate and duration
Time Frame: 2 years
|
MRD is detected by flow cytometry (FC-MRD) and second-generation gene sequencing of IgH rearrangement (NGS-MRD) after the first CAR-T (CAR-T 1) .
FC-MRD negative is defined as MRD<10-4 and NGS-MRD negative is defined as MRD<10-6.
|
2 years
|
|
Incidence of adverse events (AEs)
Time Frame: 2 years
|
AEs will be assessed according to the Common Terminology Criteria for Adverse Events 5.0 (CTCAE5.0)
after the first CAR-T (CAR-T 1) .
|
2 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in 2-year LFS between the sandwich strategy treatment and external allo-HSCT control group
Time Frame: 2 years
|
2-year LFS and 95%CI will be calculated for the sandwich strategy treatment group and external allo-HSCT control group, Log-rank P value will be provided for group comparison result.
|
2 years
|
|
Difference in 2-year OS between the sandwich strategy treatment and external allo-HSCT control group
Time Frame: 2 years
|
2-year OS and 95%CI will be calculated for the sandwich strategy treatment group and external allo-HSCT control group, Log-rank P value will be provided for group comparison result.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Infections
- Virus Diseases
- Neoplasms by Histologic Type
- DNA Virus Infections
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Tumor Virus Infections
- Hemic and Lymphatic Diseases
- Burkitt Lymphoma
Other Study ID Numbers
Other Study ID Numbers
- SZCART02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.